NICE requests Jardiance cost effectiveness data

The U.K.'s NICE issued draft guidance concerning the cost effectiveness of Type II diabetes drug Jardiance empagliflozin ( BI-10773) from partners Boehringer Ingelheim GmbH (Ingelheim, Germany) and Eli Lilly and Co. (NYSE:LLY).

NICE said Boehringer's economic model for the drug's cost effectiveness is "inherently flawed," preventing NICE from comparing it with recommended treatments. NICE asked Boehringer to deliver a revised estimation in advance of a second appraisal committee meeting Sept. 24. The committee estimated the annual cost of the drug at L470.30 ($779.29). NICE also requested revised sensitivity analyses. ...